U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008

Annals of Internal Medicine

Volumn 157, Issue 5, 2012, Pages 325-335

  Althoff, Keri N ^a   Buchacz, Kate ^b   Irene Hall, H ^b   Zhang, Jinbing ^a   Hanna, David B ^a   Rebeiro, Peter ^a   Gange, Stephen J ^a   Moore, Richard D ^c   Kitahata, Mari M ^d   Gebo, Kelly A ^c   Martin, Jeffrey ^e   Justice, Amy C ^f   Horberg, Michael A ^g   Hogg, Robert S ^h   Sterling, Timothy R ⁱ   Cescon, Angela ^h   Klein, Marina B ^j   Thorne, Jennifer E ^k   Crane, Heidi M ^d   Mugavero, Michael J ^l   Napravnik, Sonia ^m   Kirk, Gregory D ^a   Jacobson, Lisa P ^a   Brooks, John T ^b   more..

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^g Mid Atlantic Permanente Research Institute   (United States)

^h ST PAUL S HOSPITAL   (Canada)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DEATH; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; FEMALE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES; VIRUS LOAD;

EID: 84868150423     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-157-5-201209040-00005     Document Type: Article

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID: 9516219]
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9. [PMID: 18657708]
3. Centers for Disease Control and Prevention (CDC). HIV surveillance-United States, 1981-2008. MMWR Morb Mortal Wkly Rep. 2011;60:689-93. [PMID: 21637182]
4. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502. [PMID: 21826193]
5. White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. Washington, DC: White House Office of National AIDS Policy; 2010. Accessed at www.aids.gov/federal-resources/policies/national-hiv-aids-strategy/nhas.pdf on 3 July 2012.
6. McGowan CC, Weinstein DD, Samenow CP, Stinnette SE, Barkanic G, Rebeiro PF, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One. 2011;6: e18462. [PMID: 21541016]
7. Seal PS, Jackson DA, Chamot E, Willig JH, Nevin CR, Allison JJ, et al. Temporal trends in presentation for outpatient HIV medical care 2000-2010: implications for short-term mortality. J Gen Intern Med. 2011;26:745-50. [PMID: 21465301]
8. Howe CJ, Cole SR, Napravnik S, Eron JJ. Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007. AIDS Res Hum Retroviruses. 2010;26:875-81. [PMID: 20672995]
9. Belperio PS, Mole LA, Boothroyd DB, Backus LI. Trends in uptake of recently approved antiretrovirals within a national healthcare system. HIV Med. 2010;11:209-15. [PMID: 19863620]
10. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49:1570-8. [PMID: 19845472]
11. Silverberg MJ, Leyden W, Quesenberry CP Jr, Horberg MA. Race/ethnicity and risk of AIDS and death among HIV-infected patients with access to care. J Gen Intern Med. 2009;24:1065-72. [PMID: 19609624]
12. Scott JD, Wald A, Kitahata M, Krantz E, Drolette L, Corey L, et al. Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. AIDS Patient Care STDS. 2009;23:925-9. [PMID: 19827950]
13. Bozzette SA, Berry SH, Duan N, Frankel MR, Leibowitz AA, Lefkowitz D, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897-904. [PMID: 9862946]
14. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999; 281: 2305-15. [PMID: 10386555]
15. McNaghten AD, Wolfe MI, Onorato I, Nakashima AK, Valdiserri RO, Mokotoff E, et al. Improving the representativeness of behavioral and clinical surveillance for persons with HIV in the United States: the rationale for developing a population-based approach. PLoS One. 2007;2:e550. [PMID:17579722]
16. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol. 2007;36:294-301. [PMID:17213214]
17. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses. 2007;23:769-76. [PMID:17604539]
18. Centers for Disease Control and Prevention. HIV Surveillance Report, 2009. Vol. 21. Atlanta: Centers for Disease Control and Prevention; 2011.
19. Thiébaut R, Jacqmin-Gadda H. Mixed models for longitudinal left-censored repeated measures. Comput Methods Programs Biomed. 2004;74:255-60. [PMID: 15135576]
20. Hughes JP. Mixed effects models with censored data with application to HIV RNA levels. Biometrics. 1999;55:625-9. [PMID: 11318225]
21. Henrich TJ, Lauder N, Desai MM, Sofair AN. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Community Health. 2008;33:69-77. [PMID: 18046634]
22. Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care. 2007;19:637-45. [PMID: 17505924]
23. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169:656-61. [PMID: 14517122]
24. 3. J Acquir Immune Defic Syndr. 2007; 44: 179-87. [PMID: 17075385]
25. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800. [PMID:21367734]
26. Hall HI, Gray KM, Tang T, Li J, Shouse L, Mermin J. Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr. 2012;60:77-82. [PMID: 22267016]
27. Blair JM, McNaghten AD, Frazier EL, Skarbinski J, Huang P, Heffelfinger JD. Clinical and behavioral characteristics of adults receiving medical care for HIV infection--Medical Monitoring Project, United States, 2007. MMWR Surveill Summ. 2011;60(11):1-20. [PMID: 21881551]
28. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068. [PMID: 20548786]
29. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376:532-9. [PMID: 20638713]
30. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al; Partners in Prevention HSV/HIV Transmission Study Team. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29. [PMID: 21471433]
31. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505. [PMID:21767103]
32. Centers for Disease Control and Prevention. Reported CD4+ T-lymphocyte results for adults and adolescents with HIV/AIDS-33 states, 2005. HIV/AIDS Surveill Suppl Rep. 2005;11:1-31.
33. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50:1512-20. [PMID: 20415573]
34. Gandhi NR, Skanderson M, Gordon KS, Concato J, Justice AC. Delayed presentation for human immunodeficiency virus (HIV) care among veterans: a problem of access or screening? Med Care. 2007;45:1105-9. [PMID: 18049352]
35. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis. 2007;45:1369-74. [PMID: 17968837]
36. Gay CL, Napravnik S, Eron JJ Jr. Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors. AIDS. 2006;20:775-8. [PMID: 16514310]
37. Lifson AR, Krantz EM, Eberly LE, Dolan MJ, Marconi VC, Weintrob AC, et al; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group. Long-term CD4+ lymphocyte response following HAART initiation in a U.S. military prospective cohort. AIDS Res Ther. 2011;8:2. [PMID:21244701]
38. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, et al; ALLRT team. Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS. 2010;24:1867-76. [PMID:20467286]
39. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787-94. [PMID: 19193107]
40. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-6. [PMID: 17205456]
41. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al; Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24:1537-48. [PMID: 20453631]
42. Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection. 2011;39:13-20. [PMID: 21246246]
43. Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743-53. [PMID: 19571723]
44. Pacheco AG, Tuboi SH, May SB, Moreira LF, Ramadas L, Nunes EP, et al. Temporal changes in causes of death among HIV-infected patients in the HAART era in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2009;51: 624-30. [PMID: 19430304]
45. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145:397-406. [PMID: 16983127]
46. Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: The ACTG 320 trial. Am J Epidemiol. 2010;172:107-15. [PMID: 20547574]
47. Holford TR. Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health. 1991;12:425-57. [PMID:2049144]